Professor Allan Hackshaw Joins Luventix Advisory Board
Luventix, a trailblazer in Intelligent Disease Diagnostics is pleased to announce the appointment of Professor Allan Hackshaw to its Advisory Board.
Professor Hackshaw, an expert in clinical epidemiology and medical research, serves as the Director of the Cancer Research UK & UCL Cancer Trials Centre, where he is Professor of Epidemiology & Medical Statistics at University College London. He has over three decades of experience in designing and conducting impactful clinical studies across a range of disorders, with particular expertise in screening and diagnostics.
Professor Hackshaw’s expertise will be instrumental in advancing Luventix's strategic vision and research initiatives.
"We are honored to have Professor Allan Hackshaw join our Advisory Board," said George Holmes, CEO of Luventix. "His profound knowledge of clinical research and evidence-based innovation will significantly contribute to our mission to drive down the cost of healthcare by making low cost diagnostics solutions available to all!."
Professor Hackshaw’s addition underscores Luventix’s commitment to integrating world-class expertise as it continues to deliver cutting-edge solutions in urine based diagnostics.
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
